Active ingredientBelumosudilCat. No. P-B020-001CAS 911417-87-3Family · Pharmaceutical analytical standards
Belumosudil
An oral ROCK2 kinase inhibitor, approved in the United States in 2021 and in the European Union in 2026 for chronic graft-versus-host disease when other treatments have not been enough. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?The suffix -sudil links it to fasudil and netarsudil, other ROCK kinase inhibitors; belumosudil, however, specifically targets the ROCK2 isoform, and the FDA considered it first in its class.
Go to the active ingredient →Active ingredientBelumosudilCat. No. P-B020-001CAS 911417-87-3
MetaboliteBelumosudil Metabolite KD025M2Cat. No. P-B020-002CAS 911417-62-4
MetaboliteBelumosudil N-Glucuronide (N1, N2-Glucuronide Mixture)Cat. No. P-B020-003
Isotopically labelledBelumosudil-d7Cat. No. P-B020-004
NitrosamineN1-Nitroso BelumosudilCat. No. P-B020-005
NitrosamineN2-Nitroso BelumosudilCat. No. P-B020-006
NitrosamineN3-Nitroso BelumosudilCat. No. P-B020-007
ImpurityBelumosudil Impurity 1Cat. No. P-B020-008CAS 911417-89-5
ImpurityBelumosudil Impurity 2Cat. No. P-B020-009CAS 2988752-04-9
ImpurityBelumosudil Impurity 3Cat. No. P-B020-010CAS 911417-95-3
ImpurityO-Dealkylated Belumosudil O-SulfateCat. No. P-B020-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.